No Data
Announcement of Dashenlin Pharmaceutical Group Co., Ltd. on the main operating data for the first quarter of 2025
Dashenlin Pharmaceutical Group Co., Ltd. Report for the first quarter of 2025
Dashenlin Pharmaceutical Group Co., Ltd. 2024 Annual Report
Summary of the 2024 Annual Report of Dashenlin Pharmaceutical Group Co., Ltd.
Major rating｜Credit Lyonnais: The impact of the USA tariff policy on the Medical Care Industry in China is relatively small.
Lyon published a research report stating that due to the limited scale of drug trade between China and the United States, the expectation is that the Medical Care Industry in China, particularly in the field of Innovative Drugs, is relatively less affected by tariff policies. With the hope that under the optimization of centralized volume procurement and other policies, the industry is transitioning towards quality-driven growth. Therefore, there is still an optimistic view on leading innovative pharmaceutical companies and distributors in China, with a low likelihood of impact on the enterprise licensing model. Currently, Lyon's stock selection for the Medical Care Sector in China includes CSPC PHARMA, SINOPHARM, Aier Eye Hospital Group, Jiangsu Hengrui Pharmaceuticals, HANSOH PHARMA, AKESO, CMS, DaShenLin Pharmaceutical Group, Huadong Medicine, and TIGERMED.
Declining Stock and Solid Fundamentals: Is The Market Wrong About DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233)?
